Volasertib

沃拉舍替

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameVolasertib
Drug Alias Namevolasertibum伏拉色替volasertibBI-6727
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolo like kinase 1 inhibitors
TargetsPolo like kinase 1
Therapy Area/IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBahamasBelgium +[29] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaIND
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesNotable Labs LtdC.H. Boehringer Sohn Ag & Co. KgBaxter Oncology Gmbh +[5] 
Inactive CompaniesUniversity Of AlbertaYale UniversityUlm University +[4] 
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[16] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG